Prana's PBT2 benefits on Huntington's Disease published Prana Biotechnology announced that the Journal of Huntington's Disease has, in its December edition, published data showing the benefits of PBT2 in Huntington Disease. The paper describes PBT2's ability to inhibit the development of the symptoms and pathological features of Huntington Disease in pre-clinical transgenic animal models.
News For PRAN From The Last 14 Days
Check below for free stories on PRAN the last two weeks.
Prana granted orphan status for treatment of Huntington disease The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link